ArticleSarcoma2015
Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review.
Article in Sarcoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- A rare case of posterior mediastinal chondrosarcoma: a case report and brief literature review.Journal of surgical case reports · 2026Article
- Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma.Current oncology (Toronto, Ont.) · 2025Review
- Maxillary Mesenchymal Chondrosarcoma Affecting A Pediatric Patient: Case Report Showing Long-Term Follow-Up and Detailed Literature Review.Journal of maxillofacial and oral surgery · 2025Article
- Case report: Extraskeletal mesenchymal chondrosarcoma with a rare metastasis to the pancreas.Frontiers in oncology · 2024Article
- Mesenchymal Chondrosarcoma of the Mandible, a Big Dilemma: Report of a Rare Case in Mesenchymal Chondrosarcoma of the Mandible-Report of a Case With Discussion of Diagnostic and Therapeutic Dilemmas.Case reports in dentistry · 2024Article
- Review
- Mesenchymal chondrosarcoma of the head and neck with HEY1::NCOA2 fusion: A clinicopathologic and molecular study of 13 cases with emphasis on diagnostic pitfalls.Genes, chromosomes & cancer · 2022Article
- Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis.The Journal of pathology · 2022Article
- Mesenchymal chondrosarcoma of the chest wall in an adolescent patient: A case report and brief review of the literature.Cancer reports (Hoboken, N.J.) · 2022Article
- Intradural Pediatric Spinal Tumors: An Overview from Imaging to Novel Molecular Findings.Diagnostics (Basel, Switzerland) · 2021Review
- Mesenchymal chondrosarcoma: imaging features and clinical findings.Skeletal radiology · 2021Article
- Adolescent and Young Adult Oral Maxillofacial Tumors: A Single-Institution Case Series and Literature Review.Journal of adolescent and young adult oncology · 2020Review
- Chondrosarcomas in children and adolescents.EFORT open reviews · 2020Article
- Intraspinal mesenchymal chondrosarcoma: An argument for aggressive local resection and adjuvant therapy based on review of the literature.Surgical neurology international · 2020Article
- Primary mesenchymal chondrosarcoma of the kidney withoutOncology letters · 2020Article
- Robot-assisted radical nephrectomy for primary renal mesenchymal chondrosarcoma: case report and literature review.Renal failure · 2019Review
- Mesenchymal chondrosarcoma of maxilla in paediatric patient.BMJ case reports · 2019Article
- Chondrosarcoma in a paediatric population: a study of 247 cases.Journal of children's orthopaedics · 2019Article
- Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.Current oncology reports · 2018Review
- Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.Laboratory investigation; a journal of technical methods and pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Background. Mesenchymal chondrosarcoma is an aggressive, uncommon histologic entity arising in bone and soft tissues. We reviewed our institutional experience with this rare diagnosis. Methods. We conducted a retrospective chart review on patients with mesenchymal chondrosarcoma over a 24-year period. Clinicopathologic and radiographic features were reviewed. Results. Twelve patients were identified. Nine were females; median age was 14.5 years (1.2-19.7 years). The most common site was the head/neck (7/12). Disease was localized in 11/12 patients (one with lung nodules). Six with available tissue demonstrated NCOA2 rearrangement by FISH. Six underwent upfront surgical resection, and six received neoadjuvant therapy (2 chemotherapy alone and 4 chemotherapy and radiation). All patients received adjuvant chemotherapy (most commonly ifosfamide/doxorubicin) and/or radiation (median dose 59.4 Gy). At a median follow-up of 4.8 years, 5-year disease-free survival and overall survival were 68.2% (95% CI 39.8%, 96.6%) and 88.9% (95% CI 66.9%, 100%). Two patients had distant recurrences at 15 and 42 months, respectively. Conclusion. Aggressive surgical resection of mesenchymal chondrosarcoma with chemoradiotherapy yields excellent local control and may reduce likelihood of late recurrence. Characterization of downstream targets of the HEY1-NCOA2 fusion protein, xenograft models, and drug screening are needed to identify novel therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.